Immunocore Holdings plc (IMCR)Healthcare | Biotechnology | Abingdon, United Kingdom | NasdaqGS
32.49 USD
+0.54
(1.690%)
⇧
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:04 a.m. EDT
The long-term outlook remains precarious due to a deteriorating multi-year price trajectory. While the business shows signs of operational recovery with positive operating margins and accelerating quarterly earnings growth, the stock has suffered two consecutive years of negative annual returns, capping the long-term rating at a weak level. The market appears to be pricing in significant execution risk or clinical hurdles, evidenced by the heavy put positioning in the options chain which suggests investors are hedging against further declines rather than betting on a rally. With no dividend to provide income and negative earnings preventing a traditional value thesis, the investment case relies entirely on the successful commercialization of its pipeline to reverse the multi-year trend. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.073030 |
| MSTL_90 | 0.073196 |
| MSTL | 0.073221 |
| AutoARIMA | 0.073321 |
| AutoETS | 0.074191 |
| MSTL_90_115 | 0.091736 |
| MSTL_115 | 0.091760 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.70 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.008 |
| Excess Kurtosis | 0.08 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 110.671 |
| Revenue per Share | 8.172 |
| Market Cap | 1,652,622,592 |
| Forward P/E | -51.98 |
| Beta | 0.73 |
| Profit Margins | -6.68% |
| Previous Name | Immunocore Holdings Limited |
| Website | https://www.immunocore.com |
As of July 11, 2026, 6:04 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside breakout. Put volume and open interest significantly exceed call volume across all expirations, with deep out-of-the-money puts holding substantial open interest relative to the tiny call activity. This indicates a market consensus expecting further weakness or volatility to the downside, despite the stock trading near its 52-week high.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.07567567 |
| Address1 | 92 Park Drive |
| Address2 | Milton Park |
| All Time High | 76.98 |
| All Time Low | 18.43 |
| Ask | 39.92 |
| Ask Size | 2 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 681,840 |
| Average Daily Volume3 Month | 485,537 |
| Average Volume | 485,537 |
| Average Volume10Days | 681,840 |
| Beta | 0.729 |
| Bid | 23.89 |
| Bid Size | 2 |
| Book Value | 7.745 |
| City | Abingdon |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 32.49 |
| Current Ratio | 4.181 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 33.285 |
| Day Low | 30.29 |
| Debt To Equity | 110.671 |
| Display Name | Immunocore |
| Earnings Call Timestamp End | 1,772,024,400 |
| Earnings Call Timestamp Start | 1,772,024,400 |
| Earnings Growth | 1.5 |
| Earnings Quarterly Growth | 1.582 |
| Earnings Timestamp | 1,778,070,600 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -11,369,000 |
| Ebitda Margins | -0.02754 |
| Enterprise To Ebitda | -109.368 |
| Enterprise To Revenue | 3.012 |
| Enterprise Value | 1,243,409,536 |
| Eps Current Year | 0.11333 |
| Eps Forward | -0.625 |
| Eps Trailing Twelve Months | -0.56 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 29.6556 |
| Fifty Day Average Change | 2.834402 |
| Fifty Day Average Change Percent | 0.0955773 |
| Fifty Two Week Change Percent | -7.567567 |
| Fifty Two Week High | 40.715 |
| Fifty Two Week High Change | -8.224998 |
| Fifty Two Week High Change Percent | -0.20201395 |
| Fifty Two Week Low | 27.555 |
| Fifty Two Week Low Change | 4.9350014 |
| Fifty Two Week Low Change Percent | 0.1790964 |
| Fifty Two Week Range | 27.555 - 40.715 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,535,400,000 |
| Float Shares | 42,460,547 |
| Forward Eps | -0.625 |
| Forward P E | -51.984 |
| Free Cashflow | 58,577,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 524 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.32279 |
| Gross Profits | 133,253,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00066 |
| Held Percent Institutions | 1.0446601 |
| Implied Shares Outstanding | 50,865,574 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-02-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom. |
| Long Name | Immunocore Holdings plc |
| Market | us_market |
| Market Cap | 1,652,622,592 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_133103539 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-14 |
| Net Income To Common | -27,566,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,652,622,499 |
| Number Of Analyst Opinions | 12 |
| Open | 31.73 |
| Operating Cashflow | -24,922,000 |
| Operating Margins | 0.06824 |
| Payout Ratio | 0.0 |
| Phone | 44 12 3543 8600 |
| Pre Market Change | -0.020000458 |
| Pre Market Change Percent | -0.06155881 |
| Pre Market Price | 32.47 |
| Pre Market Time | 1,784,032,242 |
| Prev Name | Immunocore Holdings Limited |
| Previous Close | 31.95 |
| Price Eps Current Year | 286.6849 |
| Price Hint | 2 |
| Price To Book | 4.194965 |
| Price To Sales Trailing12 Months | 4.0033298 |
| Profit Margins | -0.06678 |
| Quick Ratio | 3.856 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.64286 |
| Region | US |
| Regular Market Change | 0.540001 |
| Regular Market Change Percent | 1.69014 |
| Regular Market Day High | 33.285 |
| Regular Market Day Low | 30.29 |
| Regular Market Day Range | 30.29 - 33.285 |
| Regular Market Open | 31.73 |
| Regular Market Previous Close | 31.95 |
| Regular Market Price | 32.49 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 892,568 |
| Return On Assets | -0.00877 |
| Return On Equity | -0.0714 |
| Revenue Growth | 0.136 |
| Revenue Per Share | 8.172 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 50,865,574 |
| Shares Percent Shares Out | 0.1768 |
| Shares Short | 8,992,351 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 8,749,260 |
| Short Name | Immunocore Holdings plc |
| Short Percent Of Float | 0.1967 |
| Short Ratio | 15.66 |
| Source Interval | 15 |
| Symbol | IMCR |
| Target High Price | 100.0 |
| Target Low Price | 34.0 |
| Target Mean Price | 63.36708 |
| Target Median Price | 61.0 |
| Total Cash | 844,896,000 |
| Total Cash Per Share | 16.61 |
| Total Debt | 435,683,008 |
| Total Revenue | 412,812,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 32.503124 |
| Two Hundred Day Average Change | -0.013122559 |
| Two Hundred Day Average Change Percent | -0.00040373224 |
| Type Disp | Equity |
| Volume | 892,568 |
| Website | https://www.immunocore.com |
| Zip | OX14 4RY |